admin – Page 3606 – Get News Story

Mydriasis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharma

The Key Mydriasis Companies in the market include – Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others.

DelveInsight’s “Mydriasis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Mydriasis, offering comprehensive insights into the Mydriasis revenue trends, prevalence, and treatment landscape. The report delves into key Mydriasis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Mydriasis therapies. Additionally, we cover the landscape of Mydriasis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Mydriasis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Mydriasis space.

To Know in detail about the Mydriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mydriasis Market Forecast

Some of the key facts of the Mydriasis Market Report:

The Mydriasis market size was valued ~USD 604 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In September 2024, Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company specializing in the development and commercialization of small molecule therapies for retinal and refractive eye conditions, has announced the publication of complete results from its two pivotal Phase 3 trials, MIRA-2 and MIRA-3. These studies assessed the safety and effectiveness of RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) for treating pharmacologically-induced mydriasis, with the findings published in the peer-reviewed journal Ophthalmology.
In 2023, the total market size for Mydriasis in the US was around USD 378.6 million, representing approximately 63% of the overall market revenue across the 7MM.
In 2023, the total market size for Mydriasis in EU4 and the UK was estimated to be around USD 150.4 million. Germany held the largest share with approximately USD 42.7 million, followed by France with USD 36.5 million, and the UK with USD 28.3 million.
In 2023, the market size for Mydriasis in Japan was estimated to be around USD 75.4 million.
In 2023, the largest market share among current therapies was held by topical treatments (eye drops/irrigation) for surgeries, generating around USD 286.2 million in the 7MM. This was followed by topical treatments (eye drops/irrigation) for eye exams, with a revenue of approximately USD 183.5 million, and OMIDRIA, which earned approximately USD 112.1 million.
Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others
Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others
The Mydriasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mydriasis pipeline products will significantly revolutionize the Mydriasis market dynamics.
DelveInsight’s epidemiology model estimates that there were around 352.1 million eye examinations and ophthalmic surgeries in the 7MM in 2023. This number is projected to grow over the forecast period (2024-2034), driven by the increasing prevalence of age-related eye conditions like cataracts, glaucoma, and macular degeneration, which are expected to result in a higher demand for eye exams and surgeries.
In 2023, out of the total eye examinations and ophthalmic surgeries in the 7MM, around 338.0 million were eye exams and check-ups. Additionally, there were approximately 8.6 million cataract surgeries, 538 thousand glaucoma surgeries, 1.6 million refractive surgeries, 505 thousand vitreoretinal surgeries, and 2.9 million cases involving other types of surgeries.
In 2023, the US made up 53% of the total eye examinations and ophthalmic surgeries, while EU4 and the UK accounted for 32%, and Japan contributed 15% of the cases.
In 2023, there were around 65.1 million instances of pupil dilation for eye examinations and approximately 5.1 million cases for eye surgeries in the EU4 countries and the UK.
In 2023, Germany led the EU4 and the UK with the highest number of pupil dilation cases, recording 16.7 million for eye examinations and 1.5 million for surgeries. France followed with about 13.5 million cases for eye examinations and 1.3 million for surgeries. Spain had the lowest figures, with 9.3 million pupil dilation cases for eye exams and 634 thousand for surgeries.
In 2023, Japan recorded approximately 29.7 million cases of pupil dilation for eye examinations and around 2.5 million cases for eye surgeries. These figures are anticipated to shift throughout the forecast period.

Mydriasis Overview

Mydriasis refers to the dilation of the pupils, which can occur naturally or be induced for medical purposes. It is commonly achieved through the use of mydriatic agents (eye drops or irrigation solutions) during eye examinations or ophthalmic surgeries to enable a better view of the retina, optic nerve, and other internal structures of the eye. Mydriasis is important for diagnosing eye conditions like cataracts, glaucoma, and retinal diseases, as well as for performing surgeries such as cataract removal and refractive surgeries. While pupil dilation is a temporary condition, it can also be a symptom of certain medical issues or neurological disorders.

Get a Free sample for the Mydriasis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/mydriasis-market

Mydriasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mydriasis Epidemiology Segmentation:

The Mydriasis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Mydriasis
Prevalent Cases of Mydriasis by severity
Gender-specific Prevalence of Mydriasis
Diagnosed Cases of Episodic and Chronic Mydriasis

Download the report to understand which factors are driving Mydriasis epidemiology trends @ Mydriasis Epidemiology Forecast

Mydriasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mydriasis market or expected to get launched during the study period. The analysis covers Mydriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mydriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mydriasis Therapies and Key Companies

RYZUMVI (Phentolamine Ophthalmic Solution 0.75%): Viatris/Ocuphire Pharma
MYDCOMBI: Eyenovia
OMIDRIA: Rayner Surgical/Omeros
MydCombi: Eyenovia Inc.
CTO0303-A: Taejoon Pharmaceutical Co., Ltd.

Discover more about therapies set to grab major Mydriasis market share @ Mydriasis Treatment Landscape

Mydriasis Market Drivers

Increasing Prevalence of Eye Conditions
Technological Advancements
Aging Population
Increased Awareness of Eye Health
Surge in Ophthalmic Surgeries

Mydriasis Market Barriers

High Cost of Treatment
Side Effects of Mydriatic Agents
Limited Availability in Low-Resource Settings
Competition from Alternative Therapies
Stringent Regulatory Approval

Scope of the Mydriasis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others
Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others
Mydriasis Therapeutic Assessment: Mydriasis current marketed and Mydriasis emerging therapies
Mydriasis Market Dynamics: Mydriasis market drivers and Mydriasis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Mydriasis Unmet Needs, KOL’s views, Analyst’s views, Mydriasis Market Access and Reimbursement

To know more about Mydriasis companies working in the treatment market, visit @ Mydriasis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Mydriasis Market Report Introduction

2. Executive Summary for Mydriasis

3. SWOT analysis of Mydriasis

4. Mydriasis Patient Share (%) Overview at a Glance

5. Mydriasis Market Overview at a Glance

6. Mydriasis Disease Background and Overview

7. Mydriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Mydriasis

9. Mydriasis Current Treatment and Medical Practices

10. Mydriasis Unmet Needs

11. Mydriasis Emerging Therapies

12. Mydriasis Market Outlook

13. Country-Wise Mydriasis Market Analysis (2020–2034)

14. Mydriasis Market Access and Reimbursement of Therapies

15. Mydriasis Market Drivers

16. Mydriasis Market Barriers

17. Mydriasis Appendix

18. Mydriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mydriasis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharma

Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen

The Key Behcet’s Disease Companies in the market include – Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others.

DelveInsight’s “Behcet’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Behcet’s Disease, historical and forecasted epidemiology as well as the Behcet’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Behcet’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Behcet’s Disease Market Forecast

Some of the key facts of the Behcet’s Disease Market Report:

The Behcet’s Disease market size was value ~USD 140 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Christopher J. Schaber, PhD, President and CEO of Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with significant unmet needs, stated that the company remains committed to advancing its diverse clinical pipeline. Key upcoming milestones include the anticipated top-line results in 2026 from the ongoing confirmatory Phase 3 placebo-controlled trial evaluating HyBryte™ (synthetic hypericin) for early-stage cutaneous T-cell lymphoma (CTCL). Additionally, in the latter half of this year, Soligenix expects to announce top-line data from its ongoing Phase 2 trials of SGX945 (dusquetide) for Behçet’s disease and SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
In November 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, announced the initiation of patient enrollment for its Phase 2 clinical trial (protocol number DUS-AUBD-01) assessing SGX945 (dusquetide) as a treatment for Behçet’s Disease.
Among the EU4 and the UK, Italy has the largest market size at around USD 10 million, followed by France with approximately USD 8 million. These figures are anticipated to change over the forecast period (2024-2034) due to ongoing research and development efforts, which may result in the discovery of more effective treatments for Behcet’s Syndrome.
In January 2024, Soligenix announced that the US Food and Drug Administration (FDA) has granted fast track designation to SGX945 (dusquetide)
In 2023, Japan had the highest number of diagnosed prevalent cases of Behcet’s syndrome among the 7MM countries.
In 2023, Italy had the highest number of diagnosed prevalent cases among the EU4 and the UK, with approximately 7,000 cases. This number is expected to increase by 2034.
In 2023, the total diagnosed prevalent cases of Behcet’s Syndrome in the US were approximately 3,500 for pediatric patients and around 16,000 for young adults.
Among the clinical manifestations of Behcet’s Syndrome in the US, oral ulcers were the most prevalent, representing about 30% of the total cases, followed by genital ulcers.
In the EU4 countries and the UK, oral ulcers were the most common, with approximately 5,000 cases, followed by genital ulcers, which accounted for around 3,000 cases.
Key Behcet’s Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
Key Behcet’s Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
The Behcet’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Behcet’s Disease pipeline products will significantly revolutionize the Behcet’s Disease market dynamics.

Behcet’s Disease Overview

Behcet’s Disease is a rare, chronic, and multisystem inflammatory disorder characterized by recurring episodes of inflammation affecting various parts of the body. It is named after the Turkish dermatologist Hulusi Behçet, who first described the condition in 1937. The disease primarily affects blood vessels, causing symptoms that can involve the mouth, eyes, skin, joints, and other organs.

Get a Free sample for the Behcet’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/behcets-disease-market

Behcet’s Disease Epidemiology

Behcet’s Disease Epidemiology Segmentation:

The Behcet’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of Behcet’s Syndrome in the 7MM
Diagnosed Cases of Behcet’s Syndrome Based on the Age of Onset in the 7MM
Clinical Manifestations Associated With Behcet’s Syndrome in the 7MM
Total Patients Seeking Treatment for Behcet’s Syndrome in the 7MM

Download the report to understand which factors are driving Behcet’s Disease epidemiology trends @ Behcet’s Disease Epidemiology Forecast

Behcet’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Behcet’s Disease market or expected to get launched during the study period. The analysis covers Behcet’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Behcet’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Behcet’s Disease Therapies and Key Companies

SGX945: Soligenix
RAY121: Chugai Pharmaceutical
Dusquetide: Soligenix
Filgotinib: UMC Utrecht
Hemay005: Ganzhou Hemay Pharmaceutical
Apremilast: Amgen

Discover more about therapies set to grab major Behcet’s Disease market share @ Behcet’s Disease Treatment Landscape

Behcet’s Disease Market Strengths

The constant efforts by researchers to determine clear molecular pathogenesis are progressively increasing.
Studies suggest that Behcet’s syndrome shares common features with autoimmune and inflammatory disorders, thus leading to the detection of the main mediators involved in the pathomechanism of Behcet’s syndrome.

Behcet’s Disease Market Opportunities

There is an attractive market for therapies with a primary goal of treatment to rapidly suppress and prevent new inflammatory attacks to avoid irreversible organ damage, especially in the early, active stages of Behcet’s syndrome.
As a consequence of escalating knowledge and awareness among providers and caregivers about Behcet’s syndrome, the prevalence of the disease is increasing, which may further expedite the R&D.

Scope of the Behcet’s Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Behcet’s Disease Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
Key Behcet’s Disease Therapies: SGX945, RAY121, Dusquetide, Filgotinib, Hemay005, Apremilast, and others
Behcet’s Disease Therapeutic Assessment: Behcet’s Disease current marketed and Behcet’s Disease emerging therapies
Behcet’s Disease Market Dynamics: Behcet’s Disease market drivers and Behcet’s Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Behcet’s Disease Unmet Needs, KOL’s views, Analyst’s views, Behcet’s Disease Market Access and Reimbursement

To know more about Behcet’s Disease companies working in the treatment market, visit @ Behcet’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Behcet’s Disease Market Report Introduction

2. Executive Summary for Behcet’s Disease

3. SWOT analysis of Behcet’s Disease

4. Behcet’s Disease Patient Share (%) Overview at a Glance

5. Behcet’s Disease Market Overview at a Glance

6. Behcet’s Disease Disease Background and Overview

7. Behcet’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Behcet’s Disease

9. Behcet’s Disease Current Treatment and Medical Practices

10. Behcet’s Disease Unmet Needs

11. Behcet’s Disease Emerging Therapies

12. Behcet’s Disease Market Outlook

13. Country-Wise Behcet’s Disease Market Analysis (2020–2034)

14. Behcet’s Disease Market Access and Reimbursement of Therapies

15. Behcet’s Disease Market Drivers

16. Behcet’s Disease Market Barriers

17. Behcet’s Disease Appendix

18. Behcet’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen

Bone Metastasis in Solid Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS

The Key Bone Metastasis in Solid Tumors Companies in the market include – Bayer HealthCare Pharmaceuticals, Amgen, Exelixis, NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others.

DelveInsight’s “Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Bone Metastasis in Solid Tumors, historical and forecasted epidemiology as well as the Bone Metastasis in Solid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bone Metastasis in Solid Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bone Metastasis in Solid Tumors Market Forecast

Some of the key facts of the Bone Metastasis in Solid Tumors Market Report:

The Bone Metastasis in Solid Tumors market size was valued ~USD 1,700 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the total market size for Bone Metastasis in Solid Tumors was approximately USD 1,700 million in the 7MM, with projections indicating growth by 2034 during the study period (2020–2034).
In 2023, the United States held the largest market share for Bone Metastasis in Solid Tumors in the 7MM, accounting for nearly 70%, surpassing the EU4, the UK, and Japan.
In 2023, the United States held the largest market share for Bone Metastasis in Solid Tumors among the 7MM, with Japan following closely behind.
The approval of pipeline candidates like Cabozantinib for Bone Metastasis in Solid Tumors during the forecast period (2024–2034) is anticipated to significantly boost the market size.
The development of NanaBis is currently moving forward in Phase III at Medlab, and if the tests are successful, an FDA NDA application might be submitted by the end of 2024
Key Bone Metastasis in Solid Tumors Companies: Bayer HealthCare Pharmaceuticals, Amgen, Exelixis, NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others
Key Bone Metastasis in Solid Tumors Therapies: XOFIGO (Radium-223 dichloride), XGEVA/RANMARK (denosumab), Cabozantinib, Medlab Clinical, Elraglusib, MW032, Ibandronate, Zoledronic acid, Fragmin, Fentanyl sublingual spray, and others
The Bone Metastasis in Solid Tumors epidemiology based on gender analyzed that men are more likely to develop bone metastasis in solid tumors than females
The Bone Metastasis in Solid Tumors market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bone Metastasis in Solid Tumors pipeline products will significantly revolutionize the Bone Metastasis in Solid Tumors market dynamics.

Bone Metastasis in Solid Tumors Overview

Bone metastasis in solid tumors refers to the spread of cancer cells from a primary solid tumor—such as lung, prostate, or breast cancer—to the bones. It is a common complication in advanced-stage cancers and can lead to bone pain, fractures, and other skeletal-related events. The condition significantly impacts a patient’s quality of life and often indicates a poor prognosis. Treatment typically focuses on managing symptoms, slowing disease progression, and maintaining bone health using therapies like bisphosphonates, radiation, and targeted treatments.

Get a Free sample for the Bone Metastasis in Solid Tumors Market Report:

https://www.delveinsight.com/report-store/bone-metastasis-in-solid-tumors-market

Bone Metastasis in Solid Tumors Epidemiology

Bone Metastasis in Solid Tumors Epidemiology Segmentation:

The Bone Metastasis in Solid Tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Bone Metastasis in Solid Tumors
Prevalent Cases of Bone Metastasis in Solid Tumors by severity
Gender-specific Prevalence of Bone Metastasis in Solid Tumors
Diagnosed Cases of Episodic and Chronic Bone Metastasis in Solid Tumors

Download the report to understand which factors are driving Bone Metastasis in Solid Tumors epidemiology trends @ Bone Metastasis in Solid Tumors Epidemiology Forecast

Bone Metastasis in Solid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bone Metastasis in Solid Tumors market or expected to get launched during the study period. The analysis covers Bone Metastasis in Solid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Bone Metastasis in Solid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bone Metastasis in Solid Tumors Therapies and Key Companies

XOFIGO (Radium-223 dichloride): Bayer HealthCare Pharmaceuticals
XGEVA/RANMARK (denosumab): Amgen
Cabozantinib: Exelixis
Medlab Clinical: NanaBis
Elraglusib: Actuate Therapeutics
MW032: Mabwell Bioscience
Ibandronate: Hoffmann-La Roche
Zoledronic acid: Novartis
Fragmin: Upjohn
Fentanyl sublingual spray: INSYS Therapeutics Inc

Discover more about therapies set to grab major Bone Metastasis in Solid Tumors market share @ Bone Metastasis in Solid Tumors Treatment Market

Scope of the Bone Metastasis in Solid Tumors Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Bone Metastasis in Solid Tumors Companies: Bayer HealthCare Pharmaceuticals, Amgen, Exelixis, NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS Therapeutics Inc, and others
Key Bone Metastasis in Solid Tumors Therapies: XOFIGO (Radium-223 dichloride), XGEVA/RANMARK (denosumab), Cabozantinib, Medlab Clinical, Elraglusib, MW032, Ibandronate, Zoledronic acid, Fragmin, Fentanyl sublingual spray, and others
Bone Metastasis in Solid Tumors Therapeutic Assessment: Bone Metastasis in Solid Tumors current marketed and Bone Metastasis in Solid Tumors emerging therapies
Bone Metastasis in Solid Tumors Market Dynamics: Bone Metastasis in Solid Tumors market drivers and Bone Metastasis in Solid Tumors market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Bone Metastasis in Solid Tumors Unmet Needs, KOL’s views, Analyst’s views, Bone Metastasis in Solid Tumors Market Access and Reimbursement

To know more about Bone Metastasis in Solid Tumors companies working in the treatment market, visit @ Bone Metastasis in Solid Tumors Clinical Trials and Therapeutic Assessment

Table of Contents

1. Bone Metastasis in Solid Tumors Market Report Introduction

2. Executive Summary for Bone Metastasis in Solid Tumors

3. SWOT analysis of Bone Metastasis in Solid Tumors

4. Bone Metastasis in Solid Tumors Patient Share (%) Overview at a Glance

5. Bone Metastasis in Solid Tumors Market Overview at a Glance

6. Bone Metastasis in Solid Tumors Disease Background and Overview

7. Bone Metastasis in Solid Tumors Epidemiology and Patient Population

8. Country-Specific Patient Population of Bone Metastasis in Solid Tumors

9. Bone Metastasis in Solid Tumors Current Treatment and Medical Practices

10. Bone Metastasis in Solid Tumors Unmet Needs

11. Bone Metastasis in Solid Tumors Emerging Therapies

12. Bone Metastasis in Solid Tumors Market Outlook

13. Country-Wise Bone Metastasis in Solid Tumors Market Analysis (2020–2034)

14. Bone Metastasis in Solid Tumors Market Access and Reimbursement of Therapies

15. Bone Metastasis in Solid Tumors Market Drivers

16. Bone Metastasis in Solid Tumors Market Barriers

17. Bone Metastasis in Solid Tumors Appendix

18. Bone Metastasis in Solid Tumors Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bone Metastasis in Solid Tumors Market Set to Grow Substantially Through 2034, DelveInsight Projects | NanaBis, Actuate Therapeutics, Mabwell Bioscience, Hoffmann-La Roche, Novartis, Upjohn, INSYS

Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals

The Key Complement 3 Glomerulopathy Companies in the market include – NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others.

DelveInsight’s “Complement 3 Glomerulopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Complement 3 Glomerulopathy, historical and forecasted epidemiology as well as the Complement 3 Glomerulopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Complement 3 Glomerulopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Complement 3 Glomerulopathy Market Forecast

Some of the key facts of the Complement 3 Glomerulopathy Market Report:

The Complement 3 Glomerulopathy market size was valued ~USD 35 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In October 2024, Novartis has reported encouraging results from the Phase III APPEAR-C3G trial, showing that Fabhalta (iptacopan), when used alongside supportive care, provided sustained improvements for patients with C3 glomerulopathy (C3G) over a 12-month period. C3G is a serious kidney disorder that frequently progresses to kidney failure within a decade of diagnosis. The APPEAR-C3G study is a Phase III, multi-center, randomized, double-blind, placebo-controlled trial aimed at evaluating the safety and effectiveness of Fabhalta, the first oral Factor B inhibitor that targets the alternative complement pathway.
In 2023, an estimated 5,760 diagnosed cases of Complement 3 Glomerulopathy (C3G) were reported across the seven major markets (7MM), with the United States accounting for around 60% of these cases—the highest among all countries—followed by Germany.
C3G is more commonly observed in adults than in the pediatric population. In Japan, around 85% of C3G cases occur in adults, while approximately 15% are seen in children.
In 2023, the total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) across the 7 major markets (7MM) was estimated to be approximately 5,760 cases.
In 2023, the diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the United States was estimated at 3,372 individuals.
Key Complement 3 Glomerulopathy Companies: NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others
Key Complement 3 Glomerulopathy Therapies: NM8074, Pegcetacoplan(APL-2), LNP023, AMY-10, iptacopan, and others
The Complement 3 Glomerulopathy epidemiology based on gender analyzed that C3GN is more prevalent than DDD
The Complement 3 Glomerulopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Complement 3 Glomerulopathy pipeline products will significantly revolutionize the Complement 3 Glomerulopathy market dynamics.

Complement 3 Glomerulopathy Overview

Complement 3 glomerulopathy (C3 glomerulopathy) refers to a group of rare kidney disorders characterized by the abnormal activation of the complement system, particularly involving complement component 3 (C3). The complement system is a part of the immune system that plays a crucial role in defending the body against infections and removing damaged cells.

Get a Free sample for the Complement 3 Glomerulopathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market

Complement 3 Glomerulopathy Epidemiology

Complement 3 Glomerulopathy Epidemiology Segmentation:

The Complement 3 Glomerulopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Complement 3 Glomerulopathy
Prevalent Cases of Complement 3 Glomerulopathy by severity
Gender-specific Prevalence of Complement 3 Glomerulopathy
Diagnosed Cases of Episodic and Chronic Complement 3 Glomerulopathy

Download the report to understand which factors are driving Complement 3 Glomerulopathy epidemiology trends @ Complement 3 Glomerulopathy Epidemiology Forecast

Complement 3 Glomerulopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complement 3 Glomerulopathy market or expected to get launched during the study period. The analysis covers Complement 3 Glomerulopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Complement 3 Glomerulopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Complement 3 Glomerulopathy Therapies and Key Companies

NM8074: NovelMed Therapeutics
Pegcetacoplan(APL-2): Apellis Pharmaceuticals
LNP023: Novartis Pharmaceuticals
AMY-10: Amyndas Pharmaceuticals

Discover more about therapies set to grab major Complement 3 Glomerulopathy market share @ Complement 3 Glomerulopathy Treatment Landscape

Complement 3 Glomerulopathy Market Strengths

The emerging market of C3G possesses several key players such as Apellis Pharmaceuticals, ChemoCentryx, and Novartis Pharmaceuticals.
The advent of novel biomarkers in the near future can shed some light on the pathophysiology of the disease, which may enhance the diagnosis of the indication.

Complement 3 Glomerulopathy Market Opportunities

Several organizations such as WeC3G, National Kidney Foundation (NKF), American Society of Nephrology (ASN), Kidney Disease: International Global Organization (KDIGO),Japanese Society of Nephrology (JSN), etc. are actively working to provide information and awareness of the disorder.

Scope of the Complement 3 Glomerulopathy Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Complement 3 Glomerulopathy Companies: NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals, and others
Key Complement 3 Glomerulopathy Therapies: NM8074, Pegcetacoplan(APL-2), LNP023, AMY-10, iptacopan, and others
Complement 3 Glomerulopathy Therapeutic Assessment: Complement 3 Glomerulopathy current marketed and Complement 3 Glomerulopathy emerging therapies
Complement 3 Glomerulopathy Market Dynamics: Complement 3 Glomerulopathy market drivers and Complement 3 Glomerulopathy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Complement 3 Glomerulopathy Unmet Needs, KOL’s views, Analyst’s views, Complement 3 Glomerulopathy Market Access and Reimbursement

To know more about Complement 3 Glomerulopathy companies working in the treatment market, visit @ Complement 3 Glomerulopathy Clinical Trials and Therapeutic Assessment

Table of Contents

1. Complement 3 Glomerulopathy Market Report Introduction

2. Executive Summary for Complement 3 Glomerulopathy

3. SWOT analysis of Complement 3 Glomerulopathy

4. Complement 3 Glomerulopathy Patient Share (%) Overview at a Glance

5. Complement 3 Glomerulopathy Market Overview at a Glance

6. Complement 3 Glomerulopathy Disease Background and Overview

7. Complement 3 Glomerulopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Complement 3 Glomerulopathy

9. Complement 3 Glomerulopathy Current Treatment and Medical Practices

10. Complement 3 Glomerulopathy Unmet Needs

11. Complement 3 Glomerulopathy Emerging Therapies

12. Complement 3 Glomerulopathy Market Outlook

13. Country-Wise Complement 3 Glomerulopathy Market Analysis (2020–2034)

14. Complement 3 Glomerulopathy Market Access and Reimbursement of Therapies

15. Complement 3 Glomerulopathy Market Drivers

16. Complement 3 Glomerulopathy Market Barriers

17. Complement 3 Glomerulopathy Appendix

18. Complement 3 Glomerulopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharmaceuticals, Novartis, Amyndas Pharmaceuticals

Systemic Lupus Erythematosus Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | GSK, AstraZeneca, Eli Lilly and Company, Biogen, Xencor, Idorsia Pharma

The Key Systemic Lupus Erythematosus Companies in the market include – GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others.

DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Systemic Lupus Erythematosus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Systemic Lupus Erythematosus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Lupus Erythematosus Market Forecast

Key Highlights from Systemic Lupus Erythematosus market Report:

The Systemic Lupus Erythematosus market size was valued ~USD 3,200 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Merck KGaA’s oral TLR7/8 inhibitor, enpatoran, did not achieve the primary endpoint in a subgroup of patients; however, the company plans to continue its development. As disclosed during the Q4 earnings call, enpatoran did not meet the primary endpoint—BILAG-Based Composite Lupus Assessment (BICLA) response at 24 weeks—in patients with systemic lupus erythematosus (SLE). The WILLOW trial (NCT05162586), a randomized, double-blind, placebo-controlled study, is evaluating the drug in 456 patients diagnosed with cutaneous lupus erythematosus (CLE) and SLE.
In October 2024, The FDA granted approval for Cullinan Therapeutics’ investigational new drug (IND) application for CLN-978, intended for the treatment of systemic lupus erythematosus (SLE).
In September 2024, Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia to begin its global Phase 1 clinical trial. The trial will evaluate CLN-978, a CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).
The United States holds the largest market size for systemic lupus erythematosus, approximately USD 2,600 million, compared to the EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Prominent companies in the Systemic Lupus Erythematosus (SLE) market, including Novartis/MorphoSys, Idorsia Pharmaceuticals/Viatris, RemeGen, and Biogen, are striving to enhance treatment options for SLE. In August 2023, AbbVie launched its Phase III Select-SLE trial to assess the efficacy of RINVOQ in treating moderate to severe SLE.
The 40–59 years age group is the most impacted by the prevalence of systemic lupus erythematosus. In 2023, across the 7MM, around 40% of the total cases were found in this age group.
In 2023, about 50% of the cases in Spain were classified as moderate.
Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
Key Systemic Lupus Erythematosus Therapies: BENLYSTA (belimumab), SAPHNELO (anifrolumab), Lupuzor, Litifilimab (BIIB059), Dapirolizumab pegol, GAZYVA, Cenerimod, DS-7011a, JMKX000189, ALPN-101, BMS-986165, Medi-546, MIL62, Nipocalimab, ianalumab, BIIB059 (litifilimab), GLPG3667, LY3471851, E6742, Obinutuzumab, Cenerimod and others
The Systemic Lupus Erythematosus epidemiology based on gender analyzed that Systemic Lupus Erythematosus is more prevalent in females
The Systemic Lupus Erythematosus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Lupus Erythematosus pipeline products will significantly revolutionize the Systemic Lupus Erythematosus market dynamics.

Systemic Lupus Erythematosus Overview:

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues and organs. It can affect various parts of the body, including the skin, joints, kidneys, brain, and other organs. Common symptoms include fatigue, joint pain, skin rashes, and fever. The cause is not fully understood but involves a combination of genetic, hormonal, and environmental factors. SLE is more common in women and often requires long-term management with medications such as anti-inflammatories, immunosuppressants, and corticosteroids to control inflammation and prevent flare-ups.

Get a Free sample for the Systemic Lupus Erythematosus Market Report:

https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market

Systemic Lupus Erythematosus Epidemiology Insights:

The epidemiology segment for Systemic Lupus Erythematosus offers information on the past and present patient populations affected by the condition and predicts future trends across seven significant countries. It aids in understanding the factors driving current and anticipated trends by examining various studies and insights from key opinion leaders.

Systemic Lupus Erythematosus Epidemiology Segmentation:

The Systemic Lupus Erythematosus market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Systemic Lupus Erythematosus
Prevalent Cases of Systemic Lupus Erythematosus by severity
Gender-specific Prevalence of Systemic Lupus Erythematosus
Diagnosed Cases of Episodic and Chronic Systemic Lupus Erythematosus

Download the report to understand which factors are driving Systemic Lupus Erythematosus epidemiology trends @ Systemic Lupus Erythematosus Epidemiology Forecast

Systemic Lupus Erythematosus Therapies and Key Companies

BENLYSTA (belimumab): GlaxoSmithKline
SAPHNELO (anifrolumab): AstraZeneca
Lupuzor: ImmuPharma
Litifilimab (BIIB059): Biogen
Dapirolizumab pegol: UCB Pharma and Biogen
GAZYVA: Hoffmann-La Roche
Cenerimod: Idorsia
DS-7011a: Daiichi Sankyo, Inc.
JMKX000189: Jemincare
ALPN-101: Alpine Immune Sciences, Inc.
BMS-986165: Bristol-Myers Squibb
Medi-546: AstraZeneca
MIL62: Beijing Mabworks Biotech
Nipocalimab: Janssen Research & Development
ianalumab: Novartis
BIIB059 (litifilimab): Biogen
GLPG3667: Galapagos NV
LY3471851: Eli Lilly and Company
E6742: Eisai Co., Ltd.
Obinutuzumab: Hoffmann-La Roche
Cenerimod: Idorsia Pharmaceuticals

Emerging Systemic Lupus Erythematosus drugs Uptake:

This section on Systemic Lupus Erythematosus concentrates on the adoption rate of newly introduced or anticipated Systemic Lupus Erythematosus medications within the market between 2020 and 2034. The evaluation includes the acceptance of these drugs within the Systemic Lupus Erythematosus market, patient adoption of various therapies, and the sales figures associated with each drug.

In September 2024, Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia to begin its global Phase 1 clinical trial. The trial will evaluate CLN-978, a CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).
Treatments of Systemic Lupus Erythematosus include NSAIDs and antimalarial agents, which are the first-line therapies for mild SLE. In addition, glucocorticoids and cytotoxic or immunosuppressive agents—such as azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and methotrexate —are used for SLE with organ involvement.

Discover more about therapies set to grab major Systemic Lupus Erythematosus market share @ Systemic Lupus Erythematosus Treatment Landscape

Systemic Lupus Erythematosus Market Forecast:

Presently, the market includes approved products for Systemic Lupus Erythematosus like BENLYSTA (belimumab) and SAPHNELO (anifrolumab-fnia).

The Systemic Lupus Erythematosus market drivers include – There is a robust pipeline for SLE with some drugs in the late stage of development, some with novel mechanisms of action, such as cenerimod, iberdomide, RSLV-132, etc. Many key players such as BMS, Pfizer, Amgen, etc., are also investigating their therapies in the mid and early stages, the diagnosed patient pool is expected to increase, which will boost the market in the coming years.

Scope of the Systemic Lupus Erythematosus Market Report:

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
Key Systemic Lupus Erythematosus Therapies: BENLYSTA (belimumab), SAPHNELO (anifrolumab), Lupuzor, Litifilimab (BIIB059), Dapirolizumab pegol, GAZYVA, Cenerimod, DS-7011a, JMKX000189, ALPN-101, BMS-986165, Medi-546, MIL62, Nipocalimab, ianalumab, BIIB059 (litifilimab), GLPG3667, LY3471851, E6742, Obinutuzumab, Cenerimod, and others
Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Systemic Lupus Erythematosus Unmet Needs, KOL’s views, Analyst’s views, Systemic Lupus Erythematosus Market Access and Reimbursement

To know more about Systemic Lupus Erythematosus companies working in the treatment market, visit @ Systemic Lupus Erythematosus Clinical Trials and Therapeutic Assessment

Table of Contents

1. Systemic Lupus Erythematosus Market Report Introduction

2. Executive Summary for Systemic Lupus Erythematosus

3. SWOT analysis of Systemic Lupus Erythematosus

4. Systemic Lupus Erythematosus Patient Share (%) Overview at a Glance

5. Systemic Lupus Erythematosus Market Overview at a Glance

6. Systemic Lupus Erythematosus Disease Background and Overview

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Country-Specific Patient Population of Systemic Lupus Erythematosus

9. Systemic Lupus Erythematosus Current Treatment and Medical Practices

10. Systemic Lupus Erythematosus Unmet Needs

11. Systemic Lupus Erythematosus Emerging Therapies

12. Systemic Lupus Erythematosus Market Outlook

13. Country-Wise Systemic Lupus Erythematosus Market Analysis (2020–2034)

14. Systemic Lupus Erythematosus Market Access and Reimbursement of Therapies

15. Systemic Lupus Erythematosus Market Drivers

16. Systemic Lupus Erythematosus Market Barriers

17. Systemic Lupus Erythematosus Appendix

18. Systemic Lupus Erythematosus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Lupus Erythematosus Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | GSK, AstraZeneca, Eli Lilly and Company, Biogen, Xencor, Idorsia Pharma

O’Connor Company Awarded $10.4M Fayetteville State University Health and Wellness Center Project

State-of-the-art wellness facility to enhance student health and campus life at Fayetteville State University

Fayetteville, NC – Apr 4, 2025 – O’Connor Company, a leading name in commercial construction specializing in delivering high-quality projects across diverse sectors, is proud to announce it has been awarded the contract for the new Fayetteville State University Health and Wellness Center, a $10.4 million project that underscores the company’s continued commitment to building community-driven, high-impact facilities across the Southeast.

The 24,500-square-foot, two-story wellness center will feature a 17,000-square-foot main level and a 7,500-square-foot second floor. Designed for durability and function, the structure will incorporate concrete foundations, CMU foundation walls, and a concrete slab-on-grade first floor. The upper floor and roof will be constructed using conventional structural steel framing, metal decking, and a Tectum roof deck.

The exterior façade will blend EIFS and an Exterior Wall Panel System, while the building will be topped with a high-performance TPO membrane roof. Interior design details include cold-formed metal framing with gypsum board partitions, CMU walls around the locker room areas, and specialized flooring tailored to each space—rubberized surfaces for fitness areas, porcelain tile for locker rooms and wet zones, sheet vinyl for general areas, and exposed concrete for mechanical and electrical rooms.

“Putting together a construction project estimate is a very collaborative and detail-driven process that requires a team effort to ensure accuracy and efficiency,” said Christine Furlich, Estimator at O’Connor Company. “Our team strives for this on every project and were able to accomplish it. I am proud of the OCC Preconstruction team that was able to develop this comprehensive, competitive bid for ownership, thrilled to have been awarded the project and excited to see the final outcome of the FSU Health and Wellness Center!”

With substantial completion targeted by the end of 2025, the project will follow an aggressive schedule requiring strong procurement planning, subcontractor coordination, and milestone tracking. O’Connor Company is well-positioned to deliver on this timeline, leveraging its experience and disciplined approach from preconstruction through closeout.

For more information about O’Connor Company and its ongoing projects, please visit https://www.buildoconnor.com.

About O’Connor Company

O’Connor Company is a leading commercial construction firm specializing in high-quality projects across diverse sectors. Known for its excellence, innovation, and integrity, O’Connor Company continues to set new standards in project delivery while building long-term value for clients and communities.

Media Contact
Company Name: Otter PR
Contact Person: Mark Hashem
Email: Send Email
Phone: 7274339069
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: O’Connor Company Awarded $10.4M Fayetteville State University Health and Wellness Center Project

Top Real Estate Agent in Kirkland, WA, Takes on Federal Political Coordinator Role to Strengthen Real Estate Advocacy in Congress

Gina Madeya, a seasoned professional in the real estate industry, is proud to announce her new role as a Federal Political Coordinator (FPC) with the National Association of REALTORS®. This position enables her to bridge the gap between local real estate concerns and national legislative efforts, ensuring that the voices of Kirkland’s homeowners and investors, as well as those across the nation, are heard at the highest levels of government. As the appointed face and voice to Senator Maria Cantwell, Gina is poised to influence housing policies that address inventory challenges and fiscal measures to enhance access to homeownership.

Raised in a family of entrepreneurs, Gina’s passion for real estate was ignited early on by her mother, a successful real estate broker. With over 25 years of corporate leadership experience at JPMorgan Chase and Microsoft, Gina brings a wealth of knowledge and a client-focused approach to her real estate practice. Her transition into real estate was driven by a desire to enhance the consumer experience through education and advocacy.

In her new role, Gina will leverage her expertise as a top Realtor in Kirkland, WA to advocate for policies that support property rights and housing affordability. “Being a seasoned real estate agent in Kirkland, WA allows me to understand the unique challenges our community faces. As an FPC, I am committed to ensuring that our voices are represented in Congress,” said Gina Madeya.

Gina’s dedication extends beyond advocacy. As a top Kirkland, WA Realtor, she has earned the Five Star REALTOR® designation, recognizing her exceptional client satisfaction and performance. Her role as a Zillow Showcase Listing Agent further underscores her commitment to providing clients with maximum exposure in the competitive real estate market.

Beyond her professional achievements, Gina serves on the Board of Directors for Alpha Supported Living Services, demonstrating her commitment to community welfare. Her multifaceted expertise as a real estate listing agent in Kirkland, WA enables her to guide not just buyers but also sellers through complex transactions with strategic and results-driven approaches. For more information about Gina Madeya and her services, visit https://www.ginamadeya.com/. Contact Gina today to experience unparalleled real estate expertise and dedicated advocacy.

Media Contact
Company Name: Gina Madeya | Real Estate Agent in Kirkland WA
Contact Person: Media Relations
Email: Send Email
Phone: +1 (425) 495-0926
Address:3933 Lake Washington Blvd NE suite 100
City: Kirkland
State: Washington 98033
Country: United States
Website: https://www.ginamadeya.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Kirkland, WA, Takes on Federal Political Coordinator Role to Strengthen Real Estate Advocacy in Congress

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

The oncology sector in the U.S. is on the verge of a transformative breakthrough. With the cancer therapeutics market already valued at over $170 billion in 2024 and expected to exceed $500 billion by 2034, the industry is experiencing a surge of innovation driven by cutting-edge treatments like immunotherapies and targeted therapies. As cancer rates continue to rise, particularly among children and underserved populations, the urgency for novel solutions has never been greater. Investors are increasingly drawn to this rapidly evolving field, where new therapies are not just improving survival rates but offering hope where there was none. With breakthroughs happening at an unprecedented pace, the oncology space presents an exciting and compelling opportunity for those looking to invest in the future of healthcare.

Now, let’s take a look at a few promising stocks in this expanding sector that could be worth keeping an eye on.

OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company that’s aiming to make a real difference in one of the toughest areas of medicine—osteosarcoma, a rare and aggressive bone cancer that mostly affects children and young adults. Their lead drug, OST-HER2, is not your typical cancer treatment. It’s an off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to kickstart the body’s immune system into attacking cancer cells that express the HER2 protein.

So far, the results have been very promising. In a Phase 2b clinical trial involving 39 patients with recurrent osteosarcoma that had spread to the lungs but was surgically removed, OST-HER2 showed a statistically significant boost in 12-month event-free survival—33% compared to 20% in similar patients who didn’t receive the treatment (p=0.0158). That’s a big deal in a cancer type where survival rates haven’t improved much in decades. “We believe OST-HER2 will make a significant difference in the treatment of osteosarcoma and welcome the opportunity to engage with FDA to get this investigational treatment to patients as quickly as possible,” said Paul Romness, CEO of OS Therapies.

And the company is moving fast. OST-HER2 has already received special FDA and European designations, including:

Rare Pediatric Disease Designation (RPDD)
Fast Track Designation
Orphan Drug Designation in both the U.S. and Europe

These help speed up the development and review process. OS Therapies is now preparing to submit a Biologics License Application (BLA) to the FDA by late 2025, with the hope of receiving Accelerated Approval shortly after.

In fact, the company recently requested a formal meeting with the FDA to agree on surrogate endpoints—essentially the key data the agency wants to see—in support of Breakthrough Therapy Designation and Accelerated Approval. That meeting is expected to happen in Q2 2025, and if all goes well, OST-HER2 could be approved by year-end. “We are excited to meet with the FDA… The goal is receiving Accelerated Approval for OST-HER2 by year-end 2025,” said Dr. Robert Petit, OS Therapies’ Chief Medical & Scientific Officer.

There’s also potential upside beyond approval. If the drug is greenlit before September 30, 2026, OS Therapies is eligible for a Priority Review Voucher (PRV)—a valuable incentive from the FDA that the company could sell. A recent PRV sold for $150 million in February 2025, and that kind of windfall could help OS Therapies fund its next programs without needing to raise more money.

OST-HER2 isn’t just being tested in people—it’s also been conditionally approved by the USDA for treating osteosarcoma in dogs, which naturally develop the disease in much the same way as humans. Dogs with cancer have been shown to respond to OST-HER2, and researchers are using this data to better understand which biomarkers might predict a strong response in people.

Why does this matter? Because human and canine osteosarcoma share 96% genetic similarity. This growing field of Comparative Oncology is giving scientists like those at OS Therapies a unique window into how these therapies might work even before full human trials are complete. The treatment—and its story—will even be featured in the upcoming PBS documentary “Shelter Me: The Cancer Pioneers.”

OST-HER2 is just the beginning. OS Therapies is also developing a next-generation Antibody Drug Conjugate (ADC) platform with tunable payloads—meaning they can design custom treatments for different cancers. This ADC program could offer future partnering or licensing opportunities, helping diversify the company’s pipeline.

Financially, OS Therapies appears solid. The company completed both an IPO and private placement in 2024, raising $12 million and projecting enough cash to operate through mid-2026. With the heaviest clinical costs now behind them, OS Therapies expects lower spending moving forward. “We expect a significantly reduced outlay beginning in the second quarter of 2025,” said Chris Acevedo, CFO of OS Therapies. “We have reduced our burn rate substantially… and expect cash on hand to last into 2026.”

Investors interested in emerging biotech should keep a close eye on OS Therapies (OSTX). With:

Strong Phase 2b results
Imminent regulatory milestones
High-value PRV opportunity
A unique canine-human comparative oncology angle
A growing immunotherapy and ADC pipeline

OSTX could be on the verge of something big. If OST-HER2 wins approval in late 2025, not only could it bring hope to children and families fighting this devastating disease, but it might also mark a major inflection point for the company’s valuation and visibility in the biotech space.

Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company that focuses on developing off-the-shelf multimodal biological immunotherapies for cancer treatment. The company’s approach includes two distinct immunotherapy platforms: one using genetically modified adenovirus (CAN-2409) and the other using herpes simplex virus (CAN-3110). CAN-2409 is currently being tested in phase 2a clinical trials for non-small cell lung cancer (NSCLC), and it has completed phase 2a and phase 3 trials in pancreatic cancer and localized prostate cancer, respectively. Meanwhile, CAN-3110, from the herpes simplex virus platform, is undergoing a phase 1b clinical trial in recurrent high-grade glioma (rHGG). Candel also employs its enLIGHTEN Discovery Platform to identify new viral immunotherapies for solid tumors.

In December 2024, Candel announced positive final survival data from a phase 2a clinical trial involving patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). Patients treated with CAN-2409 alongside standard care experienced a significant median overall survival benefit of 31.4 months, compared to just 12.5 months in the control group. The data indicated that long-term survivors in the treatment group had a substantially better survival rate, even in metastatic disease, highlighting the sustained benefits of CAN-2409. This promising data led the FDA to grant both fast-track and orphan drug designations for CAN-2409 in pancreatic cancer.

The company also revealed positive results from its phase 3 clinical trial of CAN-2409 in prostate cancer in December 2024. In this trial, CAN-2409, combined with standard radiation therapy, resulted in a 30% reduction in the risk of recurrence or death compared to the control group. In addition, the treatment arm demonstrated an 80.4% pathological complete response rate in post-treatment biopsies, compared to 63.6% in the control group. These findings are seen as a significant step toward regulatory approval for CAN-2409 in the treatment of localized prostate cancer, and the study was conducted under a Special Protocol Assessment (SPA) with the FDA.

Candel also provided an update on its phase 1b trial of CAN-3110 in recurrent high-grade glioma (rHGG). Data presented at the 6th Annual International Oncolytic Virotherapy Conference in October 2024 showed promising early survival outcomes, with three out of six patients surviving for over a year following repeated doses of CAN-3110. The company received both fast-track and orphan drug designations from the FDA for CAN-3110 in rHGG. Furthermore, Candel entered into a strategic partnership with IDEA Pharma, a biopharmaceutical strategy consultancy, in 2024. This collaboration will provide commercial insights into the development and commercialization of CAN-2409. Additionally, Dr. Elizabeth M. Jaffee, a leading pancreatic cancer expert, joined the company’s Research Advisory Board, enhancing its focus on advancing treatments for pancreatic cancer.

In April 2025, Candel published the results of a phase 1b trial exploring the combination of CAN-2409 with nivolumab and standard care in newly diagnosed high-grade glioma patients. The data showed that the combination was well tolerated and resulted in extended survival for a subset of patients. A notable finding was the increase in T cell receptor (TCR) density and diversity, which correlated with improved survival outcomes. This reinforces the potential of CAN-2409 as a treatment for a wide range of solid tumors.

Financially, Candel reported research and development expenses of $4.8 million for the fourth quarter of 2024, down from $7.3 million the previous year. General and administrative expenses increased slightly to $3.3 million for the quarter. The company posted a net loss of $14.1 million for the quarter, compared to a net loss of $11.1 million in the same period the previous year. For the full year 2024, Candel’s net loss amounted to $55.2 million, up from $37.9 million in 2023. As of December 31, 2024, the company had $102.7 million in cash and equivalents, which is expected to fund its operations into the first quarter of 2027.

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) is a biopharmaceutical company that is making significant strides in the fight against pediatric cancer, particularly high-risk neuroblastoma. Neuroblastoma is a rare and aggressive cancer that mainly affects children, and Y-mAbs is dedicated to improving the outcomes for patients who are facing this challenging disease. The company has developed DANYELZA (naxitamab), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. This breakthrough treatment offers hope to children who have exhausted other therapy options.

One of the most promising aspects of Y-mAbs is its work with naxitamab, a treatment that has shown strong efficacy in clinical trials. According to a Phase 2 clinical trial published in Nature Communications, naxitamab demonstrated a 50% overall response rate (ORR) among patients with relapsed or refractory high-risk neuroblastoma. Notably, the therapy showed particularly strong results in targeting residual disease in the bone and bone marrow, which are common areas where cancer cells hide and resist traditional chemotherapy.

Naxitamab is an anti-GD2 monoclonal antibody, meaning it targets the GD2 molecule found on the surface of neuroblastoma cells. This therapy is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that boosts the immune system to fight cancer. In clinical trials, naxitamab has shown manageable safety and promising efficacy, with many patients achieving a partial or complete response. In fact, 58% of patients with bone disease saw a positive response, making it an essential option for those who haven’t responded to other treatments.

Y-mAbs has been actively working to expand the reach of DANYELZA globally. In 2024, the company reported significant revenue growth from its international markets, particularly in Europe and Asia. With DANYELZA now available in 69 U.S. centers and expanding into new regions, the company is well-positioned to bring this life-saving treatment to more children in need.

As of early 2025, Y-mAbs has adjusted its business strategy to focus on expanding the clinical development of its Radiopharmaceuticals Platform, alongside continuing to drive the growth of DANYELZA. The company has a robust pipeline, including its innovative SADA PRIT technology, which could open up new avenues for treating solid tumors in pediatric cancer patients.

Despite a net loss in 2024, Y-mAbs is focusing on cost efficiency and capital investment to fuel future growth. With a strong balance sheet and clear plans to expand its clinical and commercial efforts, Y-mAbs could offer significant upside potential for investors interested in the growing field of pediatric cancer therapeutics.

For investors looking to support innovative treatments in pediatric cancer, Y-mAbs Therapeutics presents a unique opportunity, with a solid product, promising clinical data, and an evolving strategy for growth.

Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) is making significant strides in pediatric cancer treatment, tackling one of the most critical areas of unmet need in the oncology space. The company’s lead drug, OJEMDA (tovorafenib), is a promising targeted therapy designed to treat pediatric low-grade glioma (pLGG), a rare brain tumor that predominantly affects children.

OJEMDA is a Type II RAF kinase inhibitor, targeting BRAF mutations that are common in pLGG. Approved by the FDA under accelerated approval, the treatment is a breakthrough in a field where treatment options have been limited. Since its launch in April 2024, OJEMDA has shown strong sales, with net product revenues of $57.2 million for the full year. In the first eight months post-launch, over 1,600 prescriptions were written, highlighting the demand for new therapies in this space.

Day One has positioned OJEMDA as a cornerstone of its pipeline, and the company is already advancing its clinical strategy with a global, pivotal Phase 3 trial called FIREFLY-2. Full enrollment in the trial is expected by the first half of 2026, which could pave the way for further regulatory progress. Additionally, OJEMDA received Exclusively Pediatric designation from the Centers for Medicare & Medicaid Services in late 2024, which is expected to reduce the rebate percentage for the drug, further supporting its commercial viability.

The company’s financial outlook appears solid, with a year-end 2024 cash balance of $531.7 million, providing a strong runway for future growth. Day One is also making progress in other areas, including its development of DAY301, a targeted antibody-drug conjugate (ADC), which has entered early-stage clinical trials. If successful, DAY301 could add to Day One’s growing pipeline and diversify its offerings in the pediatric oncology market.

While Day One recorded a net loss in 2024, the company’s focus on expanding access to OJEMDA and advancing its pipeline positions it well for long-term success. For investors, Day One represents a unique opportunity to support innovation in pediatric cancer therapeutics, with a promising product, a strong pipeline, and a dedicated team pushing the boundaries of what’s possible in cancer treatment.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

Lone Wolf Roofing: Metairie’s Top Roofer Revolutionizing the Roofing Industry

Lone Wolf Roofing has established itself as Metairie’s leading roofing and siding provider while simultaneously pushing the industry toward innovation and excellence. Under the guidance of owner Clare Manale, the company has transformed how Louisiana homeowners approach exterior improvements.

What distinguishes Lone Wolf from traditional roofing companies is their forward-thinking approach to climate challenges. Rather than applying standard solutions, they’ve developed specialized techniques and material combinations specifically engineered to combat Louisiana’s hurricanes, extreme humidity, and intense heat. This climate-focused methodology has revolutionized durability expectations for local roofing projects.

The company’s innovative spirit extends across their service offerings, which include advanced roofing systems, high-performance siding installations, energy-efficient window replacements, and custom patio constructions. Each service incorporates the latest industry advancements while maintaining the highest standards of craftsmanship.

Their commitment to excellence has earned them prestigious certifications, including Fortified Roofer, GAF Master Elite Contractor, and IKO PREFERRED Contractor status. The GAF Master Elite designation is particularly significant, as it’s awarded to only the top 2% of roofing contractors nationwide. This certification reflects their exceptional installation quality, customer satisfaction, and commitment to ongoing professional development.

Details of the Certifications and Awards:

2022-2025 Better Business Bureau (BBB)
2018-2024 Jefferson Parish Recreation Department Coach Volunteer for Youth Growth & Development
2024 Expertise.com Top Roofer of the Year in Metairie, LA
2020-2024 Expertise.com Top 17 Roofers of the Year in Metairie, LA
2020-2024 Volunteers at Second Harvest Food Bank
2020-2024 Quality Business Award Nominee
2023-2024 Outstanding Workmanship Award Via National Roofing Contractor Association Winner
2022 Louisiana Contractor’s Association Certificate for Roofing Excellence
2020-2025 GAF Master Elite Residential Roofing Contractor
2023-2025 IBHS Fortified Certified Roofing Contractor Hurricane, Hail, & Wind
2023 ENR Top 20 Under 40
2022-2024 Top 100 Contractors in USA via RoofingContractor.com
2021-2024 Malarkey Roofing Shingles Installment Certification
2021-2024 IKo preferred roofer

Some of the key advantages that Lone Wolf Roofing offers include:

Trusted Expertise: Holding dual certifications as a Fortified Roofer and a GAF Master Elite Roofer, Lone Wolf Roofing provides expert skills and proven experience.
Extended Warranties: With their GAF Master Elite designation, the firm can offer extended warranties that surpass the typical coverage most contractors provide, guaranteeing your roof stays safeguarded for years.
High-Quality Materials and Methods: They construct each roof employing the most advanced materials and techniques, guaranteeing optimal durability and efficiency.
Customer-Focused Service: Lone Wolf Roofing is committed to putting customers first. The team collaborates closely with clients to address their requirements from the first consultation to the ultimate installation.
Professional Advice: Their experienced staff assists clients in grasping the advantages of fortified and GAF Master Elite roofing, steering them towards informed choices.
Effortless Setup: From initial planning to final execution, Lone Wolf Roofing manages all facets of the project with expertise and attention.
Thorough Assistance: Whether responding to inquiries, resolving issues, or providing extended guarantees, the organization is committed to ensuring customer fulfillment.

With Fortified Certification, Lone Wolf Roofing has solidified its position as a leader in the roofing and siding space. Every installation done by Lone Wolf Roofing adheres to rigorous industry standards for weather resistance and durability. Whether it’s a coastal zone prone to hurricanes or a location famous for severe hail, Lone Wolf Roofing ensures that it always provides long-lasting solutions as per the needs of the local residents.

To learn more about the top roofer in Metairie, Louisiana, contact Lone Wolf Roofing at 504-230-6512 or book a free consultation.

To learn more, visit https://lonewolfroofs.com/.

For updates, follow Lone Wolf Roofing on social media: https://linktr.ee/lonewolfroofing

About the Company:

Lone Wolf Roofing specializes in providing high-quality roofing solutions that meet rigorous Fortified and GAF Master Elite standards. The company is known for its commitment to durability, professional expertise, and customer satisfaction.

Media Contact
Company Name: Lone Wolf Roofing
Contact Person: Support
Email: Send Email
City: Metairie
State: Louisiana
Country: United States
Website: www.lonewolfroofs.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lone Wolf Roofing: Metairie’s Top Roofer Revolutionizing the Roofing Industry

Eazy Peace Announces Global Expansion with Launch of International Website

Eazy Peace, a brand rooted in meaningful designs and cultural storytelling, has officially announced its global expansion with the launch of its international website. The brand, which began as a passion project in India in November 2023, will now serve customers across the USA, UK, EU, Singapore, Japan, UAE, and Canada. This milestone marks a significant step in sharing Eazy Peace’s unique apparel and heartfelt designs with a worldwide audience.

“Eazy Peace was born from love—love for my son, my family, and the joy of creating something that makes people feel connected,” said Ms. B Sahu, founder of Eazy Peace.

Ms. B Sahu started Eazy Peace as a personal endeavor to create clothing that felt meaningful and full of love. Originally inspired by designs for her newborn son, the brand quickly gained attention from family and friends before evolving into a full-fledged business. Since its inception, Eazy Peace has been celebrated for its distinctive T-shirts that blend personal stories with cultural messages.

Cultural Connection Through Limited Edition Designs

As part of its global launch, Eazy Peace is introducing limited edition T-shirts featuring text-based cultural designs from India. These exclusive pieces aim to connect people worldwide with the deeper stories and values embedded in each design. The brand’s offerings cater to diverse audiences, including moms, dads, kids, siblings, and grandparents, as well as those seeking customized apparel for events or businesses.

“Every design tells a story and carries a message. Going global isn’t just about expansion; it’s about sharing something meaningful with the world and celebrating what makes us unique,” Ms. B Sahu added.

For more information or to explore the new global collection, visit www.eazypeace.com.

For updates, follow Eazy Peace on social media:

Instagram: @eazypeaceofficial

Facebook: Eazy Peace Store

Pinterest: Eazy Peace

LinkedIn: Eazy Peace

About Eazy Peace

Eazy Peace is more than just an apparel brand—it’s a platform for connection through design. With a focus on meaningful storytelling and cultural resonance, the company offers T-shirts that inspire joy and unity while celebrating individuality. From its origins in India to its current headquarters in Spain, Eazy Peace continues to bring people together through thoughtfully crafted designs.

Media Contact
Company Name: Eazy Peace
Contact Person: Ms. B Sahu
Email: Send Email
City: Benavente
State: Zamora
Country: Spain
Website: www.eazypeace.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eazy Peace Announces Global Expansion with Launch of International Website